SCHEMBL23544752

SCHEMBL23544752

COc1cc2nccc(Oc3ccc(NC(=O)N(C)C)c(Cl)c3)c2cc1C(N)=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.73
PDGFRA P16234 8/20 0.73
AURKB Q96GD4 6/20 0.73
RET P07949 5/20 0.73
PDGFRB P09619 4/20 0.73
KIT P10721 3/20 0.73
FGFR1 P11362 3/20 0.73
FLT1 P17948 3/20 0.73
FLT4 P35916 3/20 0.73
ABL1 P00519 3/20 0.73
RIPK2 O43353 2/20 0.73
STK10 O94804 2/20 0.73
BCR P11274 2/20 0.73
SLC6A3 Q01959 2/20 0.73
DDR1 Q08345 2/20 0.73
MAP4K2 Q12851 2/20 0.73
PTK6 Q13882 2/20 0.73
DDR2 Q16832 2/20 0.73
RIPK3 Q9Y572 2/20 0.73
ERN1 O75460 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20927363 0.91 KDR (0.71) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL19957002 0.91 KDR (0.71) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL1890089 0.91 KDR (0.77) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL23366513 0.91 KDR (0.83) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL2177590 0.90 KDR (0.76) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL19072630 0.90 KDR (0.76) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL19957067 0.89 KDR (0.75) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL19957141 0.89 KDR (0.75) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL863668 0.88 KDR (0.79) KDRPDGFRAAURKBRETPDGFRB
SCHEMBL26726698 0.88 KDR (0.73) KDRPDGFRAAURKBRETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107305202-B HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard 北京睿创康泰医药研究院有限公司 2020-04-17 CN claimed
US-11236050-B2 Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2022-02-01 US disclosed
US-20210188778-A1 NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2021-06-24 US disclosed
CN-107305202-B HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard 北京睿创康泰医药研究院有限公司 2020-04-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236050-B2 Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof UGT1A1, CYP4B1, CYP1B1 KDR 4267/4885PDGFRA 1620/4885AURKB 3656/4885
US-20210188778-A1 NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF CYP4B1, UGT1A1, CYP3A4 KDR 4133/4885PDGFRA 1316/4885AURKB 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.